GHRS vs GNPX

GH Research PLC vs Genprex, Inc. — Valuation Comparison 2026

GHRS

Biotechnology
GH Research PLC
Quality
4.4
out of 10
Value Trap
12
SAFE
Price
$22.38
Last close
Models
7/13
Active
VS

GNPX

Biotechnology
Genprex, Inc.
Quality
3.9
out of 10
Value Trap
24
SAFE
Price
$0.79
Last close
Models
7/13
Active

Model-by-Model Comparison

ModelType GHRS Fair ValueGHRS Upside GNPX Fair ValueGNPX Upside
Bayesian DCF Intrinsic $3.69 -83.5% $1.15 +44.2%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $•••.•• ••.•% $•••.•• ••.•%
Dynamic NAV Asset-Based $2.62 -88.3% $2.93 +269.2%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for GHRS vs GNPX — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

GHRS vs GNPX — Which Stock Is More Undervalued?

GHRS scores higher with a 4.4/10 quality rating vs GNPX's 3.9/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing GH Research PLC (GHRS) and Genprex, Inc. (GNPX) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

GHRS currently trades at $22.38 with a QOC of 4.4/10, while GNPX trades at $0.79 with a QOC of 3.9/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).